Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma

20 Dec 2020

Abstract excerpt

Serine–threonine protein kinase B-RAF (BRAF)-mutated metastatic melanoma (MM) is a highly aggressive type of skin cancer. Treatment of MM patients using BRAF/MEK inhibitors (BRAFi/MEKi) eventually leads to drug resistance, limiting any clinical benefit. Herein, we demonstrated that the nicotinamide adenine dinucleotide (NAD)-biosynthetic enzyme nicotinamide phosphoribosyltransferase (NAMPT) is a driving factor in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cutaneous Melanoma Detection and Management
Share to Immunotherapy and Immune Responses
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33419372
DOI: 10.3390/cancers12123855

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in MelanomaPMID 33419372Read ↗

Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma.Semantic proximity Read ↗

NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic TargetsSemantic proximity Read ↗

Tumors carrying BRAF-mutations over-express NAMPT that is genetically amplified and possesses oncogenic properties.Semantic proximity Read ↗

Treatment Resistance to Melanoma Therapeutics on a Single Cell LevelSemantic proximity Read ↗

Treatment resistance to melanoma therapeutics on a single cell level.Semantic proximity Read ↗

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read ↗

ROS induction as a strategy to target persister cancer cells with low metabolic activity in NRAS mutated melanomaSemantic proximity Read ↗

PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanomaSemantic proximity Read ↗

ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma.Semantic proximity Read ↗

Redirecting resistance evolution in <i> BRAF <sup>V600</sup> </i> melanoma by inhibition of the peroxiredoxin-thioredoxin systemSemantic proximity Read ↗

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic PlasticitySemantic proximity Read ↗

The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.